Wednesday, January 7, 2009
pehel.com
Home Latest News Pakistan World Science / Technology Sports Entertainment Health Business


BiPar Sciences Expands Phase 2 Clinical Trials Of BSI-201, A Novel DNA Repair Inhibitor, In Ovarian Cancer
Source: Medical News Today E-Mail this News Story to a friend E-Mail this Story
Category: Health
Publication Date: Fri, 09 May 2008 00:00:00 PDT
News URL: http://www.medicalnewstoday.com/articles/106845.php
BiPar Sciences Expands Phase 2 Clinical Trials Of BSI-201, A Novel DNA Repair Inhibitor, In Ovarian CancerBiPar Sciences, Inc. announced the expansion of Phase 2 clinical trial programs for its lead product, BSI-201, in ovarian cancer. This is the third major clinical trial of BSI-201 that BiPar has launched in the past 6 months, expanding on on going trials in breast and brain cancer.
Click here for full Story
http://www.medicalnewstoday.com/articles/106845.php
Bookmark this news story online:
Add BiPar Sciences Expands Phase 2 Clinical Trials Of BSI-201, A Novel DNA Repair Inhibitor, In Ovarian Cancer to BlinkListAdd BiPar Sciences Expands Phase 2 Clinical Trials Of BSI-201, A Novel DNA Repair Inhibitor, In Ovarian Cancer to DeliciousAdd BiPar Sciences Expands Phase 2 Clinical Trials Of BSI-201, A Novel DNA Repair Inhibitor, In Ovarian Cancer to DiggAdd BiPar Sciences Expands Phase 2 Clinical Trials Of BSI-201, A Novel DNA Repair Inhibitor, In Ovarian Cancer to FarkAdd BiPar Sciences Expands Phase 2 Clinical Trials Of BSI-201, A Novel DNA Repair Inhibitor, In Ovarian Cancer to FurlAdd BiPar Sciences Expands Phase 2 Clinical Trials Of BSI-201, A Novel DNA Repair Inhibitor, In Ovarian Cancer to BlogarithmAdd BiPar Sciences Expands Phase 2 Clinical Trials Of BSI-201, A Novel DNA Repair Inhibitor, In Ovarian Cancer to MeneameAdd BiPar Sciences Expands Phase 2 Clinical Trials Of BSI-201, A Novel DNA Repair Inhibitor, In Ovarian Cancer to My Yahoo!Add BiPar Sciences Expands Phase 2 Clinical Trials Of BSI-201, A Novel DNA Repair Inhibitor, In Ovarian Cancer to ReddItAdd BiPar Sciences Expands Phase 2 Clinical Trials Of BSI-201, A Novel DNA Repair Inhibitor, In Ovarian Cancer to ShadowsAdd BiPar Sciences Expands Phase 2 Clinical Trials Of BSI-201, A Novel DNA Repair Inhibitor, In Ovarian Cancer to SimpyAdd BiPar Sciences Expands Phase 2 Clinical Trials Of BSI-201, A Novel DNA Repair Inhibitor, In Ovarian Cancer to SpurlAdd BiPar Sciences Expands Phase 2 Clinical Trials Of BSI-201, A Novel DNA Repair Inhibitor, In Ovarian Cancer to Sync2ItAdd BiPar Sciences Expands Phase 2 Clinical Trials Of BSI-201, A Novel DNA Repair Inhibitor, In Ovarian Cancer to MagnoliaAdd BiPar Sciences Expands Phase 2 Clinical Trials Of BSI-201, A Novel DNA Repair Inhibitor, In Ovarian Cancer to NewsVineAdd BiPar Sciences Expands Phase 2 Clinical Trials Of BSI-201, A Novel DNA Repair Inhibitor, In Ovarian Cancer to Ask Jeeves
Add BiPar Sciences Expands Phase 2 Clinical Trials Of BSI-201, A Novel DNA Repair Inhibitor, In Ovarian Cancer to Raw SugarAdd BiPar Sciences Expands Phase 2 Clinical Trials Of BSI-201, A Novel DNA Repair Inhibitor, In Ovarian Cancer to DiigoAdd BiPar Sciences Expands Phase 2 Clinical Trials Of BSI-201, A Novel DNA Repair Inhibitor, In Ovarian Cancer to NetVouzAdd BiPar Sciences Expands Phase 2 Clinical Trials Of BSI-201, A Novel DNA Repair Inhibitor, In Ovarian Cancer to Stumble UponAdd BiPar Sciences Expands Phase 2 Clinical Trials Of BSI-201, A Novel DNA Repair Inhibitor, In Ovarian Cancer to SegnaloAdd BiPar Sciences Expands Phase 2 Clinical Trials Of BSI-201, A Novel DNA Repair Inhibitor, In Ovarian Cancer to Google BookmarksAdd BiPar Sciences Expands Phase 2 Clinical Trials Of BSI-201, A Novel DNA Repair Inhibitor, In Ovarian Cancer to Microsoft LiveAdd BiPar Sciences Expands Phase 2 Clinical Trials Of BSI-201, A Novel DNA Repair Inhibitor, In Ovarian Cancer to BlogMarksAdd BiPar Sciences Expands Phase 2 Clinical Trials Of BSI-201, A Novel DNA Repair Inhibitor, In Ovarian Cancer to WinkAdd BiPar Sciences Expands Phase 2 Clinical Trials Of BSI-201, A Novel DNA Repair Inhibitor, In Ovarian Cancer to TechnoratiAdd BiPar Sciences Expands Phase 2 Clinical Trials Of BSI-201, A Novel DNA Repair Inhibitor, In Ovarian Cancer to Feed Me LinksAdd BiPar Sciences Expands Phase 2 Clinical Trials Of BSI-201, A Novel DNA Repair Inhibitor, In Ovarian Cancer to LinkaGoGoAdd BiPar Sciences Expands Phase 2 Clinical Trials Of BSI-201, A Novel DNA Repair Inhibitor, In Ovarian Cancer to BlueDotAdd BiPar Sciences Expands Phase 2 Clinical Trials Of BSI-201, A Novel DNA Repair Inhibitor, In Ovarian Cancer to Mister WongAdd BiPar Sciences Expands Phase 2 Clinical Trials Of BSI-201, A Novel DNA Repair Inhibitor, In Ovarian Cancer to TailRankAdd BiPar Sciences Expands Phase 2 Clinical Trials Of BSI-201, A Novel DNA Repair Inhibitor, In Ovarian Cancer to Yahoo Bookmarks

Comments

No comments found... be the first one to comment on this story :)

Post a Comment
Name:
   
E-Mail Address:
   
Website / Blog URL (optional):
   
Comments:
   
Security Code:
   
  
   By submitting these comments, you are agreeing to our Terms of Service
    
Latest News
Latest News World News Pakistan News Technology News Entertainment News Business News Sports News
bullet World Medical Association Pleads For Physicians' Access To Patients And Medical Facilities In Gaza
bullet From Popcorn To Nuts In Diverticulosis: Good-bye To An Old Chestnut
bullet Forensic Issues In Child Sexual Abuse Allegations
bullet Insanity Defense Evaluations - Basic Procedure And Best Practices
bullet Sheffield Teaching Hospitals NHS Foundation Trust Delivers Same Day Patient Discharge Via Bighand Digital Dictation
bullet Journal Of The American Dietetic Association January 2009
bullet Get Fit For Free, UK
bullet A Protein That Protects Against Alzheimer's?
bullet British Veterinary Association Adds Two New Services For Members Of The Young Vet Network
bullet Familial Susceptibility For Degenerative Brain Disease Caused By Genetic Mutation
bullet Special Issue Of Lymphatic Research And Biology Honors Judah Folkman, M.D
bullet Testes Stem Cell Can Change Into Other Body Tissues, Stanford/UCSF Study Shows
bullet 'Relocation' Plan Of Metastatic Cancer Cells Uncovered By Stanford Researchers
bullet Protein Has Pivotal Role In Obesity, Metabolic Syndrome
bullet Medtronic Announces Clinical Trial Of Stent For Peripheral Arterial Disease
bullet Medtronic Launches Its First Integrated Power Console (IPC™) Platform For Use In Spinal, Cranial, And Ear, Nose, And Throat Surgeries
bullet Orphan Drug Designation In Gastric Cancer For Tesetaxel, A Leading Oral Taxane In Clinical Development
bullet Protective Gene Variant Becomes Bad Actor On A High-Fat Diet
bullet Idera Pharmaceuticals Announces Publication Of Studies On Chemistry Of Novel Antagonists For Toll-like Receptors 7 And 9
bullet Sensitivity To Appetite Suppressant Fat Hormone Restored By Approved Drugs
bullet Science Of Health Care Disparities Meeting To Be Hosted By American Association For Cancer Research, AZ
bullet Association For Medical Ethics Releases Ethical Rules Of Disclosure
bullet Gout: Clues To Clinical Diagnosis
bullet First Science From The Compact Light Source: A Miniature Synchrotron For Your Home Lab
bullet New Collaborative Journal Launches, Highlights Latest Sports Medicine Research
 
© 2007 Verge Systems